CMC support for ncats rare disease platform gene therapy trial projects
Active Awarded Last action
- Contract number
- 75N91019F00138
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $30,072,496
Award facts
- Opportunity
-
- N02CO7240681 Solicitation number
- Contract value 100% obligated
- $30,072,495.87 Current and potential, with all options
- Completion date 61% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $1,809,442 | |
| Other Administrative Action | $4,167,482 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $2,478,621 | |
| Other Administrative Action | $2,014,484 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $5,077,161 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $1,777,461 | |
| Funding Only Action | $1,284,221 | |
| Other Administrative Action | $414,862 | |
| Supplemental Agreement for work within scope | $7,268,296 | |
| Funding Only Action | $218,703 | |
| Original award | $3,561,763 |
Show all 15
About this award
The National Cancer Institute issued a delivery order to Leidos Biomedical Research Inc. on September 23, 2019, with a ceiling value of $30,072,495.87 for CMC support for NCATS rare disease platform gene therapy trial projects. The order is cost-plus-fixed-fee and has an ultimate completion date of March 31, 2031.
Place of performance is Frederick, MD. Leidos Biomedical Research operates the Frederick National Laboratory for Cancer Research on behalf of NCI and delivers biomedical research and clinical trial support services across the NIH ecosystem.
Service Contract Inventory reporting shows invoiced labor activity spanning FY2020–FY2025. FY2025 (the most recent reported year) reflects 14.7 FTEs across 30,492 contractor hours at a derived government-paid hourly rate of $33.76/hr. The order engaged one subcontractor for 86% of contractor hours in FY2025. Across the full reporting period, invoiced activity peaked in FY2023 at $4.2 million (12.5 FTEs, 25,922 hours) and declined to $931 thousand in FY2024 before rebounding to $1 million in FY2025, indicating variable year-over-year demand aligned with project phase progression.
Quick answers
Who was awarded contract 75N91019F00138?
75N91019F00138 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 23, 2019.
How much is contract 75N91019F00138 worth?
The government has obligated $30,072,496 on 75N91019F00138.
Is contract 75N91019F00138 an order under another contract?
Yes. 75N91019F00138 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91019F00138 competed?
The extent of competition for 75N91019F00138 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award